Your search for oral corticosteroids returned 59 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

News remove

Your search for oral corticosteroids returned 59 results

Sort Results:

Relevant Recent
ASH 2010

Carfilzomib Has Potential to Offer Substantial Clinical Benefit to Patients With Relapsed/Refractory Multiple Myeloma; Subset Analysis Finds No Impact of Baseline Peripheral Neuropathy on Efficacy

Treatment with single-agent carfilzomib achieved durable responses in patients with relapsed/refractory multiple myeloma whose disease had relapsed after they received all available therapies (including bortezomib and immunomodulatory agents), suggesting that this agent has the potential to offer substantial clinical benefit. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.
Drugs in the Pipeline

Phase 3 study of LX211 (Luveniq) for uveitis

Lux Biosciences reported the results from three Phase 3 LUMINATE trials of the company's LX211 (Luveniq, voclosporin capsules) drug candidate for the treatment of uveitis.
News

Promacta approved for chronic ITP

The FDA has approved Promacta tablets (eltrombopag, from GlaxoSmithKline) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have been unresponsive to corticosteroids, immunoglobulins or splenectomy.
News

Trivaris approved for ocular inflammation

The FDA has approved Trivaris (triamcinolone acetonide injectable suspension, from Allergan), a synthetic glucocorticoid corticosteroid, for sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.
Uncategorized

Baxter suspends multi-dose heparin production

Baxter Healthcare has temporarily stopped manufacturing multi-dose vials of heparin sodium for injection due to reports of serious allergic reactions and hypotension in patients who receive high bolus doses of the drug.
News

Triesence approved for eye surgery

The FDA has approved Triesence 40mg/mL (triamcinolone acetonide injectable suspension, from Alcon), a preservative-free synthetic corticosteroid for use in eye surgery and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.